$Moderna, Inc.(MRNA)$ Today's session set up a decent backdrop for pricing Moderna's convertible notes. Even with a sizable $2.0 billion offering announced, potentially going up to $2.3 billion, the stock recovered from an intraday drop of nearly 7% and finished down only 4.6% at around $142.82. That looks like the market absorbed most of the initial convertible-arbitrage selling and dilution worries without really damaging the post-melanoma-data revaluation. Moderna got a good financing window right after its Phase 3 oncology readout. The company can now strengthen its balance sheet, possibly refinance more expensive debt, and fund oncology investment through 2032 with no regular interest, while the capped call should substantially limit dilution. If the final conversion price lands around $200 or higher and the additional $300 million tranche gets exercised, this deal should be seen as highly favorable and would materially weaken the short thesis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
